Anebulo Pharmaceuticals, Inc.

NasdaqCM:ANEB Voorraadrapport

Marktkapitalisatie: US$51.5m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Anebulo Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Richie Cunningham

Algemeen directeur

US$1.8m

Totale compensatie

Percentage CEO-salaris18.3%
Dienstverband CEOless than a year
Eigendom CEOn/a
Management gemiddelde ambtstermijn1.8yrs
Gemiddelde ambtstermijn bestuur3.6yrs

Recente managementupdates

Recent updates

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 22
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Feb 18
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Jul 03
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 07
Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Nov 19
We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Anebulo Pharmaceuticals to launch private investment in public equity financing

Sep 26

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

Sep 09

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 28
Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 15
Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals reports FQ3 results

Jun 21

Analyse CEO-vergoeding

Hoe is Richie Cunningham's beloning veranderd ten opzichte van Anebulo Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024US$2mUS$333k

-US$8m

Compensatie versus markt: De totale vergoeding ($USD 1.82M ) Richie } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Richie te vergelijken met de prestaties van het bedrijf.


CEO

Richie Cunningham (53 yo)

less than a year

Tenure

US$1,819,383

Compensatie

Mr. Richard Anthony Cunningham, also known as Richie, is Chief Executive Officer and Director of Anebulo Pharmaceuticals, Inc. since October 2023. He served as Chief Executive Officer and Director at Tyme...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Joseph Lawler
Founder & Chairman4.5yrsUS$83.11k46.27%
$ 23.8m
Richard Cunningham
CEO & Directorless than a yearUS$1.82mgeen gegevens
Daniel George
Principal Accounting Officer1.1yrsUS$194.25kgeen gegevens
Kenneth Cundy
Chief Scientific Officer2.4yrsUS$612.15k0%
$ 0

1.8yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ANEB wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.


Bestuursleden

NaamPositieTenureCompensatieEigendom
Joseph Lawler
Founder & Chairman4.5yrsUS$83.11k46.27%
$ 23.8m
Richard Cunningham
CEO & Directorless than a yearUS$1.82mgeen gegevens
Bimal Shah
Independent Directorless than a yearUS$124.53kgeen gegevens
Kenneth Lin
Lead Independent Director3.7yrsUS$68.24k0%
$ 0
Areta Kupchyk
Independent Director3.5yrsUS$76.87k0%
$ 0
Jason Aryeh
Independent Director3.6yrsUS$83.24k0%
$ 0
Nathaniel Calloway
Independent Director2yrsUS$67.26kgeen gegevens
Aron English
Independent Director4.3yrsUS$66.87k17.95%
$ 9.2m
Andrew Monte
Member of Scientific Advisory Board3.8yrsgeen gegevensgeen gegevens
Arjun Chanmugam
Member of Scientific Advisory Board3.8yrsgeen gegevensgeen gegevens

3.6yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ANEB wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).